Management Team

Charlie Cohen, PhD - Chairman/Chief Executive Officer

Charles Cohen, PhD has spent the past 28 years working as an entrepreneur, senior executive and investor in the biopharmaceutical industry and has focused on healthcare and life science venture capital since 2003. Charles is a co-founder of Synthesis Capital, where he focuses on investments in private companies in the biopharmaceutical and medical technology industries. From 2003 to 2007, Dr. Cohen was a Partner at the global private equity firm Advent International as a member of the healthcare and life science venture deal team. His responsibilities include sourcing, evaluating and managing portfolio company investments across the HCLS II and HCLS III funds. Prior to joining Advent, Dr. Cohen was a successful serial entrepreneur, having co-founded or served as senior executive/Board member of eleven companies, seven of which were Advent portfolio companies including Cellzome (acquired by GlaxoSmithKline) and leading public companies such as Exelixis (Nasdaq:EXEL) and Anadys Pharmaceuticals (Nasdaq:ANDS, acquired by Roche). Prior to this, in 1982 Dr. Cohen co-founded Creative BioMolecules (Nasdaq:CBMI, which merged with two other biotechnology companies in 2000 and now trades as Nasdaq:CRIS) and was a director and its Chief Executive Officer from 1985 to 1995. In addition Dr. Cohen served as special advisor to Paine Webber where he served as a director of several clinical R&D partnerships, including those affiliated with Genzyme (Nasdaq:GENZ, acquired by Sanofi), Cephalon (Nasdaq:CEPH, acquired by Teva), Alkermes (Nasdaq:ALKS) and ICOS (Nasdaq:ICOS, acquired by Eli Lilly). Charles currently serves as a member of the Advisory Council to the Harvard University Technology Development Accelerator Fund and a director of Foundation Sante.

Dr. Cohen is currently an active Board Member of the following portfolio companies: Ampla Pharmaceuticals, Exelixis (Nasdaq:EXEL), Prexa Pharmaceuticals and Sirion Therapeutics (sold to Alcon and Bausch & Lomb).

Charles received a BA from the University of New York at Buffalo, a PhD from New York University School of Medicine and completed a post doctoral fellowship at the University of Virginia.

Ev (Evelyn) Graham, MBA - Chief Operating Officer

Ms. Graham has demonstrated scientific, operational and leadership skills in public and private pharmaceutical, contract research, and biotechnology firms for more than 25 years. Ms. Graham was the Chief Executive Officer and a member of the Board of Directors of TorreyPines Therapeutics, Inc., a public biotech company focused on developing novel small molecules to treat diseases and disorders of the CNS. Ms. Graham joined TorreyPines in 2004 as Vice President, Development and was Chief Operating Officer from 2006 to 2008. Prior to joining TorreyPines, Ms. Graham held senior managementpositions at Purdue Pharma; Ingenix Pharmaceutical Services, a division of UHG; Worldwide Clinical Trials, Inc.; and Bayer Corporation. Ms. Graham formerly served on the Board of Directors of CalciMedica, Inc. a private biotech company focusing on the discovery and development of small molecules to treat immune disorders.

Ms. Graham holds a BA in Biology from the University of Delaware and an MBA from the University of Connecticut.

Philip Huxley, PhD - Chief Technology Officer

Dr Huxley has more than 20 years experience in the pharmaceutical industry and has played a key role in the identification of four clinical candidates. His recent work focuses on SAR exploration and translational research: turning basic science and early stage drug discovery projects into clinical candidates with data packages supporting safety, efficacy and in vivo proof of principle.

Dr. Huxley began his career as a computational chemist with Novartis (Basel) and has subsequently held positions of increasing seniority with British Biotech (Head of Molecular Design), Avidex (Head of Drug Discovery), and Galapagos Genomics (Director of Drug Discovery). At British Biotechnology Dr Huxley co-invented CHR-2797, a metalloenzyme inhibitor that exerts a selective anti-cancer effect through inhibition of intracellular aminopeptidases. CHR-2797 was progressed into pivotal trials targeting haematological tumours in 2011. At Avidex he led the team which discovered the worlds first orally active CD80 inhibitor, which progressed from an early led compound to pre-clinical development within two years of project commencement. At Galapagos, Dr Huxley was a co-inventor of the companies first development candidate, GLPG0259, and established the collaboration between Galapagos and Biofocus, which culminated in the merger of the two companies to form a combined group offering integrated Target and Drug Discovery services.

The author of more than 30 articles and patents, Dr. Huxley obtained a BSc in chemistry from the University of Aberdeen and a D.Phil. in computational chemistry from the University of Sussex. Dr. Huxley is an advisor to Professor M. Radahakrishna Pillais group at the Rajiv Ghandi Centre for Biotechnology (Kerala, India) where he has been assisting in the discovery and development of novel protein capture technologies and Spear Therapeutics, a UK based virtual company working on the discovery and development of novel cancer therapies.

Patricia P. Baskin, MA - Executive Director, Development

Ms. Pat Baskin has more than 13 years experience in drug research and development including director level responsibility for all nonclinical development programs and regulatory interactions at small and large CNS-focused pharmaceutical and biotechnology companies. Pats research and development work includes characterizing the pharmacology of gamma secretase inhibitors and modulators at SIBIA Neurosciences, Merck & Co., and TorreyPines Therapeutics. A neuroscientist by training, while at TorreyPines, Pat was responsible for managing nonclinical development for three CNS product candidates. Pats responsibilities included all aspects of developing and managing IND-enabling plans, preparing FDA briefing documents, writing the nonclinical sections of INDs and attending pre-IND and End of Phase 2 meetings with the FDA.

Pat received her MA in Psychology and Neurosciences from the University of Connecticut.

back to top